Can Gilead And Merck Capitalize On AstraZeneca/Daiichi Sankyo’s TROP2 Safety Concerns?

Dato-DXd’s Lung Adverse Events Could Scupper NSCLC Goals

 
• By Andrew McConaghie
  
Gilead_USA
Gilead's Trodelvy is the first TROP2 ADC on the market - Dato-DXd could still outperform it in breast cancer, but safety issues may hamper its progress in NSCLC
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D